Improving treatments for lung cancer with specific MET mutations
Official title: Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14
Funded at Fred Hutchinson Cancer Center · NIH-11062982 · Data updated 2026-11-12
This study is looking at lung cancer patients with changes in the MET gene to find out how these changes affect treatment, so we can discover better therapy options for everyone dealing with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | April 1, 2019 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $140,086 |
| NIH project number | 7R01CA239604-06 |
| Project ID | NIH-11062982 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lung cancer patients who have been diagnosed with MET exon 14 mutations.
✕Less likely to help
Patients without MET mutations or those with other types of lung cancer may not benefit from this research.
What this research studies
This research focuses on lung cancer, particularly on patients with mutations in the MET gene, which can affect treatment outcomes. The team aims to optimize targeted therapies by understanding how these mutations influence the effectiveness of existing MET inhibitors. By characterizing the specific changes in the MET gene, the researchers hope to identify better treatment options for a larger group of lung cancer patients. The study will involve laboratory experiments to analyze how these mutations interact with various therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective targeted treatments for lung cancer patients with MET mutations.
How similar studies have gone: Previous research has shown promising results in targeting specific mutations in lung cancer, indicating potential success for this approach.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Collisson, Eric — Fred Hutchinson Cancer Center
- Study coordinator: Collisson, Eric
Related research
Other NIH-funded projects on the same topics.
-
TRIM28 Inhibition for NOTCH2-Mutant Small Cell Lung Cancer
A new approach aims to exploit a weakness in a subset of small cell lung cancer by turning on immune-related signals when NOTCH2 is lost, potentially making tumors more visible to the immune system.
-
Genomic factors shaping lung cancer risk in Native Hawaiians and Pacific Islanders
This NIH grant focuses on understanding why Native Hawaiians, Pacific Islanders, and African Americans have higher lung cancer risk and poorer outcomes by studying tumor DNA and related molecular patterns.
-
PD-L1 PET tracer to guide immune therapy in non-small cell lung cancer
A Johns Hopkins team is testing a Gallium-68 PET tracer to better guide immune checkpoint therapy for people with non-small cell lung cancer.
-
Targeting SMARCA2 to treat lung cancers that lack SMARCA4
This work looks at whether blocking a protein called SMARCA2 can slow or stop lung cancers that have lost the related gene SMARCA4.
-
New medicines for lung cancers caused by KRAS or BRAF changes
Testing new medicines that block ERK/RAF signaling in people with lung cancer driven by KRAS or BRAF mutations.
-
Understanding lung cancer risks in Native Hawaiians
This research looks at the genetic differences in lung cancer among Native Hawaiians to better understand why they face higher risks and poorer outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.